Fimepinostat

N/A

Report date: 2024/02/02 17:52:10
NMEFirst In Class

Base Information

Drug NameFimepinostat
Drug Alias NameCUDC-907
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase inhibitorsPI3-kinase class I inhibitors
TargetsHistone deacetylasePI3-kinase class I
Therapy Area/IndicationsSolid tumoursNUT midline carcinomaCushing Syndrome +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerlandSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCuris Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteCuris IncUniversity Of California, Los Angeles
Inactive CompaniesNational Cancer Institute
Active IndicationsSolid tumoursCushing SyndromeBrain Neoplasms +[10] 
Inactive IndicationsNUT midline carcinomaThyroid NeoplasmsOvarian Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank